GLP1R and type 2 diabetes mellitus: Recent pre-specified CV meta-analyses of prospectively adjudicated events also suggest that treatment with the longer-acting GLP-1 RAs, albiglutide and taspoglutide, does not increase the risk of MACE in patients with T2D [28, 29].